TransMed7 Announces President Appointment

PORTOLA VALLEY, Calif.--(BUSINESS WIRE)--TransMed7, LLC, today announced the appointment of Edgar D. Staren, MD, PhD, MBA, as TransMed7’s President as well as President of Martinet Medical, LLC, a new subsidiary Project Company among its portfolio, effective July 1, 2017. “Dr. Staren brings more than 20 years’ experience as a successful healthcare executive leading clinical programs, facilities, and biotechnology startups as well as operations management in both for-profit and not-for-profit arenas,” said Eugene H. Vetter, TransMed7’s Co-Founder and CEO. “In his new role, he will be responsible for taking our overall business strategy to the next level, as well as managing operations, quality, and financial performance for both TransMed7 and each of our Project Companies. Dr. Staren will also lead our efforts to substantially expand our presence in the greater Phoenix area and the Southwest U.S. market. We are fortunate to be able to add Dr. Staren’s leadership and experience to our mix, and look forward to the new impetus he brings to the growth of our business.”

Most recently Dr. Staren was Professor of Surgery, VP and Executive Director for Cancer Services at Wake Forest University Baptist Health, and Deputy Director for Clinical Affairs of its Comprehensive Cancer Center where he fostered tremendous growth in cancer services, enhanced clinical efficiencies, and drove substantial increase in operating income. Immediately prior to this he served as CEO of Ashion PMed Management, LLC, and President of its subsidiary, Ashion Advanced Individual Medicine, LLC, both outgrowths of the Translational Genomic Research Institute (TGen) and now an affiliate of the City of Hope Comprehensive Cancer Center.

A graduate of Loyola University School of Medicine, Dr. Staren received his surgical training at Rush University Medical Center and Cook County Hospitals; he remained at Rush as a faculty member where he held positions as Professor and Associate Dean. He subsequently was recruited as Professor and Chairman of Surgery at the Medical College of Ohio and Medical Director of the MCO Cancer Institute. He then served as SVP and Chief Medical Officer, Western Regional Medical Center CEO, and CEO of CTCA Medicine and Science before joining Ashion. Dr. Staren has been regularly listed in “Best Doctors in America” and “America’s Top Doctors for Cancer.” He is a member of numerous academic organizations including the American Surgical Association, the American Society of Clinical Oncology, the Society of Surgical Oncology and is a Past President of the American Society of Breast Surgeons. He has published nearly 300 scientific works including more than 150 manuscripts, 80+ abstracts, 45 book chapters, and 12 books. He has given more than 200 visiting professorships or invited lectures. “I feel most fortunate to be joining a remarkably talented team dedicated to bringing their combined expertise to bear in order to make a difference in the lives of patients in need,” says Dr. Staren.

According to Dr. James W. Vetter, TransMed7 Co-Founder and Chairman, “Dr. Staren has been a pioneer and strong advocate for the enhanced use of minimally invasive, image-guided procedures throughout his career. Along with his proven operational excellence, Dr. Staren brings his extensive experience with the latest diagnostic and treatment advances to further advance TransMed7’s prime objective of improving each patient’s treatment, care and quality of life through practical translation of new capabilities and concepts into our pipeline of transformational devices.”

About TransMed7, LLC

TransMed7, LLC is a medical and technology based organization focused on the highly efficient development of innovative, minimally invasive medical devices aimed at providing new solutions for doctors and their patients. With particular expertise in both oncologic and cardiovascular disease, TransMed7 and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices that are expected to be market leaders in their targeted fields of medicine. TransMed7 accomplishes this through application of a wholly new approach in its business plan and structure, enabling these new transformational technologies from rapid development through commercial manufacturing or where appropriate, handoff to our Strategic Partners. For more information about TransMed7, please visit our website at www.transmed7.com.